Skip to main content
SpringerLink
Log in

Growth Hormone Insensitivity

  • Chapter
  • First Online:
Pediatric Endocrinology

Part of the book series: Contemporary Endocrinology ((COE))

  • 2690 Accesses

Abstract

GH insensitivity (GHI) or resistance is defined as the absence of an appropriate growth and metabolic response to endogenous growth hormone (GH) or to GH administered at physiologic replacement dosage. The genetic disorders that interfere with the response to GH include mutations affecting the GH receptor (GHR), serum transducers, and activator of transcription 5b (STAT5b), acid-labile subunit (ALS), insulin-like growth factor I (IGF-I), and IGF-I receptor.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rosenbloom AL. Physiology and disorders of the growth hormone receptor (GHR) and GH-GHR signal transduction. Endocrine. 2000;12:107–19.

    Article  PubMed  CAS  Google Scholar 

  2. Postel-Vinay M-C, Kelly PA. Growth hormone receptor signalling. Baillieres Clin Endocrinol Metab. 1996;10:323–6.

    Article  PubMed  CAS  Google Scholar 

  3. Godowski PJ, Leung DW, Meacham LR, et al. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. Proc Natl Acad Sci USA. 1989;86:8083–7.

    Article  PubMed  CAS  Google Scholar 

  4. de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. 1992;255:306–12.

    Article  PubMed  Google Scholar 

  5. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev. 1997;18:801–31.

    Article  PubMed  CAS  Google Scholar 

  6. Baxter RG, Binoux MA, Clemmons DR, Conover CA, Drop SLA, Holly JMP, et al. Recommendations for nomenclature of the insulin-like growth factor binding proteins superfamily. J Clin Endocrinol Metab. 1998;83:3213.

    Article  PubMed  CAS  Google Scholar 

  7. Vaccarello MA, Diamond Jr FB, Guevara-Aguirre J, et al. Hormonal and metabolic effects and pharmacokinetics of recombinant human insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. J Clin Endocrinol Metab. 1993;77:273–80.

    Article  PubMed  CAS  Google Scholar 

  8. Daughaday WH, Rotwein P. Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev. 1989;10:68–91.

    Article  PubMed  CAS  Google Scholar 

  9. Rosenbloom AL. Growth hormone insensitivity: physiologic and genetic basis, phenotype, and treatment. J Pediatr. 1999;135:280–9.

    Article  PubMed  CAS  Google Scholar 

  10. Rivarola MA, Phillips III JA, Migeon CJ, Heinrich JJ, Hjelle BJ. Phenotypic heterogeneity in familial isolated growth hormone deficiency type I-A. J Clin Endocrinol Metab. 1984;59:34–40.

    Article  PubMed  CAS  Google Scholar 

  11. Powell DR. Effects of renal failure on the growth hormone-insulin-like growth factor axis. J Pediatr. 1997;131:S13–516.

    Article  PubMed  CAS  Google Scholar 

  12. Ayling RM, Ross R, Towner P, et al. A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet. 1997;16:13–4.

    Article  PubMed  CAS  Google Scholar 

  13. Iida K, Takahashi Y, Kaji H, et al. Growth hormone (GH) insensitivity syndrome with high serum GH binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain. J Clin Endocrinol Metab. 1998;83:531–7.

    Article  PubMed  CAS  Google Scholar 

  14. Iida K, Takahashi Y, Kaji H, et al. Functional characterization of truncated growth hormone (GH) receptor (1-277) causing partial GH insensitivity syndrome with high GH-binding protein. J Clin Endocrinol Metab. 1999;84:1011–6.

    Article  PubMed  CAS  Google Scholar 

  15. Dastot F, Sobrier ML, Duquesnoy P, Duriez B, Goosens M, Amselem S. Alternative spliced forms in the cytoplasmic domain of the human growth hormone (GH) receptor regulate its ability to generate a soluble GH binding protein. Proc Natl Acad Sci USA. 1996;93:10723–8.

    Article  PubMed  CAS  Google Scholar 

  16. Metherell LA, Akker SA, Munroe PB, et al. Pseudoexon activation as a novel mechanism for disease resulting in atypical growth hormone insensitivity. Am J Hum Genet. 2001;69:641–6.

    Article  PubMed  CAS  Google Scholar 

  17. Rosenfeld RG, Belgorosky A, Camacho-Hubner C, Savage MO, Wit JM, Hwa V. Defects in growth hormone receptor signaling. Trends Endocrinol Metab. 2007;18:134–41.

    Article  PubMed  CAS  Google Scholar 

  18. Cofanova-Gambetti OV, Hwa V, Jorge AAL, et al. Heterozygous STAT5b gene mutations: impact on clinical phenotype. In: Endocrine Society annual meeting, June 19–22; 2010, San Diego, abstract P1-661.

    Google Scholar 

  19. Woods KA, Camacho-Hübner C, Savage MO, Clark AJL. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Eng J Med. 1996;335:1363–7.

    Article  CAS  Google Scholar 

  20. Bonapace G, Concolino D, Formicola S, Strisciuglio P. A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiency. J Med Genet. 2003;40:913–7.

    Article  PubMed  CAS  Google Scholar 

  21. Walenkamp MJ, Karperien M, Pereira AM, et al. Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab. 2005;90:2855–64.

    Article  PubMed  CAS  Google Scholar 

  22. Netchine I, Azzi S, Houang M, et al. Partial primary deficiency of insulin-like growth factor (IGF)-I activity associated with IGF-I mutation demonstrates its critical role in growth and brain development. J Clin Endocrinol Metab. 2009;94:3913–21.

    Article  PubMed  CAS  Google Scholar 

  23. Domené HM, Bengolea SV, Martínez AS, Ropelato MG, Pennisi P, Scaglia P. Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med. 2004;350:570–7.

    Article  PubMed  Google Scholar 

  24. Hwa V, Haeusler G, Pratt KL, Little BM, Frisch H, Koller D. Total absence of functional acid labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab. 2006;91:1826–31.

    Article  PubMed  CAS  Google Scholar 

  25. Domené HM, Scaglia PA, Lteif A, et al. Phenotypic effects of null and haploinsufficiency of acid-labile subunit in a family with two novel IGFALS gene mutations. J Clin Endocrinol Metab. 2007;92:4444–50.

    Article  PubMed  Google Scholar 

  26. Heath KE, Argente J, Barrios V, Pozo J, Díaz-González F, Martos-Moreno GA. Primary acid-labile subunit deficiency due to recessive IGFALS mutations results in postnatal growth deficit associated with low circulating insulin growth factor (IGF)-I, IGF binding protein-3 levels, and hyperinsulinemia. J Clin Endocrinol Metab. 2008;93:1616–24.

    Article  PubMed  CAS  Google Scholar 

  27. van Duyvenvoorde HA, Kempers MJ, Twickler TB, van Doorn J, Gerver WJ, Noordam C. Homozygous and heterozygous expression of a novel mutation of the acid-labile subunit. Eur J Endocrinol. 2008;159:113–20.

    Article  PubMed  Google Scholar 

  28. Fofanova-Gambetti OV, Hwa V, Kirsch S, Pihoker C, Chiu HK, Högler W. Three novel IGFALS gene mutations resulting in total ALS and severe circulating IGF-I/IGFBP-3 deficiency in children of different ethnic origins. Horm Res. 2009;71:100–10.

    Article  PubMed  CAS  Google Scholar 

  29. Fofanova-Gambetti OV, Hwa V, Wit JM, et al. Impact of heterozygosity for acid-labile subunit (IGFALS) gene mutations on stature: results from the international acid-labile subunit consortium. J Clin Endocrinol Metab. 2010;95:4184–91.

    Article  PubMed  CAS  Google Scholar 

  30. Domené HM, Martínez AS, Frystyk J, et al. Normal growth spurt and final height despite low levels of all forms of circulating insulin-like growth factor-I in a patient with acid-labile subunit deficiency. Horm Res. 2007;67:243–9.

    Article  PubMed  Google Scholar 

  31. Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med. 2003;349:2211–22.

    Article  PubMed  CAS  Google Scholar 

  32. Kawashima Y, Kanzaki S, Yang F, Kinoshita T, Hanaki K, Nagaishi J. Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation. J Clin Endocrinol Metab. 2005;90:4679–87.

    Article  PubMed  CAS  Google Scholar 

  33. Walenkamp MJ, van der Kamp HJ, Pereira AM, Kant SG, van Duyvenvoorde HA, Kruithof MF. A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the insulin-like growth factor I receptor. J Clin Endocrinol Metab. 2006;91:3062–70.

    Article  PubMed  CAS  Google Scholar 

  34. Inagaki K, Tiulpakov A, Rubtsov P, Sverdlova P, Peterkova V, Yakar S. A familial insulin-like growth factor-I receptor mutant leads to short stature: clinical and biochemical characterization. J Clin Endocrinol Metab. 2007;92:1542–8.

    Article  PubMed  CAS  Google Scholar 

  35. Walenkamp MJ, de Muinck Keizer-Schrama SM, de Mos M, Kalf ME, van Duyvenvoorde HA, Boot AM. Successful long-term growth hormone therapy in a girl with haploinsufficiency of the insulin-like growth factor-I receptor due to a terminal 15q26.2->qter Deletion detected by multiplex ligation probe amplification. J Clin Endocrinol Metab. 2008;93:2421–5.

    Article  PubMed  CAS  Google Scholar 

  36. Fang P, Schwartz ID, Johnson BD, Derr MA, Roberts Jr CT, Hwa V. Familial short stature caused by haploinsufficiency of the insulin-like growth factor i receptor due to nonsense-mediated messenger ribonucleic acid decay. J Clin Endocrinol Metab. 2009;94:1740–7.

    Article  PubMed  CAS  Google Scholar 

  37. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone—a new inborn error of metabolism? Isr J Med Sci. 1966;2:152–5.

    PubMed  CAS  Google Scholar 

  38. Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Fielder PJ. The little women of Loja. Growth hormone receptor-deficiency in an inbred population of southern Ecuador. N Engl J Med. 1990;323:1367–74.

    Article  PubMed  CAS  Google Scholar 

  39. Rosenbloom AL, Francke U, Rosenfeld RG, Guevara-Aguirre J. Growth hormone receptor deficiency in Ecuador. J Clin Endocrinol Metab. 1999;84:4436–43.

    Article  PubMed  CAS  Google Scholar 

  40. Rudling M, Norstedt G, Olivecrona H, Reihnér E, Gustafsson J-A, Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci USA. 1992;89:6983–7.

    Article  PubMed  CAS  Google Scholar 

  41. Guevara-Aguirre J, Guevara-Aguirre M, Saavedra J. Low serum levels of IGF-I, BP3 and ALS are associated to severe short stature, obesity, premature aging, increased cardiovascular mortality and absence of cancer in the Ecuadorian cohort of Laron syndrome subjects. In: Pediatric Academic Societies annual meeting, Toronto, Canada; 2007. Abstract #327.

    Google Scholar 

  42. Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Pollock BH. Growth in growth hormone insensitivity. Trends Endocrinol Metab. 1994;5:296–303.

    Article  PubMed  CAS  Google Scholar 

  43. Laron Z, Lilos P, Klinger B. Growth curves for Laron syndrome. Arch Dis Child. 1993;68:768–70.

    Article  PubMed  CAS  Google Scholar 

  44. Rose SR, Municchi G, Barnes KM, Kamp GA, Uriarte MM, Ross JL, Cassorla F, Cutler Jr GB. Spontaneous growth hormone secretion increases during puberty in normal girls and boys. J Clin Endocrinol Metab. 1991;73:428–35.

    Article  PubMed  CAS  Google Scholar 

  45. Crosnier H, Gourmelen M, Prëvot C, Rappaport R. Effects of nutrient intake on growth, insulin-like growth factors, and their binding proteins in a Laron-type dwarf. J Clin Endocrinol Metab. 1993;76:248–50.

    Article  PubMed  CAS  Google Scholar 

  46. Schaefer GB, Rosenbloom AL, Guevara-Aguirre J, et al. Facial morphometry of Ecuadorian patients with growth hormone receptor deficiency/Laron syndrome. J Med Genet. 1994;31:635–9.

    Article  PubMed  CAS  Google Scholar 

  47. Rosenbloom AL, Selman-Almonte A, Brown MR, Fisher DA, Baumbach L, Parks JS. Clinical and biochemical phenotype of familial anterior hypopituitarism from mutation of PROP-1 gene. J Clin Endocrinol Metab. 1999;84:50–7.

    Article  PubMed  CAS  Google Scholar 

  48. Rosenbloom AL, Guevara-Aguirre J, Fielder PJ, Gargosky S, Rosenfeld RG, Diamond Jr FB, Vaccarello MA. Growth hormone receptor deficiency/Laron syndrome in Ecuador: clinical and biochemical characteristics. Pediatr Adolesc Endocrinol. 1993;24:34–52.

    Google Scholar 

  49. Bachrach LB, Marcus R, Ott SM, Rosenbloom AL, Vasconez O, Martinez V, Martinez AL, Rosenfeld RG, Guevara-Aguirre J. Bone mineral, histomorphometry, and body composition in adults with growth hormone receptor deficiency. J Bone Miner Res. 1998;13:415–21.

    Article  PubMed  CAS  Google Scholar 

  50. Bandeira F, Camargo K, Caldas G, Rosenbloom AL, Stabler B, Underwood LE. Primary growth hormone insensitivity: case report. Arq Bras Endocrinol Metab. 1997;41:198–200.

    Google Scholar 

  51. Frankel JJ, Laron Z. Psychological aspects of pituitary insufficiency in children and adolescents with special reference to growth hormone. Isr J Med Sci. 1968;4:953–61.

    PubMed  CAS  Google Scholar 

  52. Galatzer A, Aran O, Nagelberg N, Rubitzek J, Laron Z. Cognitive and psychosocial functioning of young adults with Laron syndrome. Pediatr Adolesc Endocrinol. 1993;24:53–60.

    Google Scholar 

  53. Woods KA, Dastot F, Preece MA, et al. Extensive personal experience. Phenotype: genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab. 1997;82:3529–35.

    Article  PubMed  CAS  Google Scholar 

  54. Guevara-Aguirre J, Rosenbloom AL. Psychosocial adaptation of Ecuadorian patients with growth hormone receptor deficiency/Laron syndrome. Pediatr Adolesc Endocrinol. 1993;24:61–4.

    Google Scholar 

  55. Kranzler JH, Rosenbloom AL, Martinez V, Guevara-Aguirre J. Normal intelligence with severe IGF-I deficiency due to growth hormone receptor deficiency: a controlled study in genetically homogeneous population. J Clin Endocrinol Metab. 1998;83:1953–8.

    Article  PubMed  CAS  Google Scholar 

  56. Zhou Y, Xu BC, Maheshwari HG, He H, et al. A mammalian model for the Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci USA. 1997;94:13215–20.

    Article  PubMed  CAS  Google Scholar 

  57. Beck KD, Powell-Braxton L, Widmer H-R, Valverde J, Hofti F. IGF-I gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron. 1995;14:717–30.

    Article  PubMed  CAS  Google Scholar 

  58. Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev. 1994;15:369–90.

    PubMed  CAS  Google Scholar 

  59. Maheshwari HG, Silverman BI, Dupuis J, Baumann G. Phenotype and genetic analysis of a syndrome caused by an inactivating mutation in the growth hormone-releasing hormone receptor: dwarfism of Sindh. J Clin Endocrinol Metab. 1998;83:4065–74.

    Article  PubMed  CAS  Google Scholar 

  60. Gargosky SE, Wilson KF, Fielder PJ, et al. The composition and distribution of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients: effects of IGF-I therapy on IGFBP-3. J Clin Endocrinol Metab. 1993;77:1683–9.

    Article  PubMed  CAS  Google Scholar 

  61. Wilson KF, Fielder PJ, Guevara-Aguirre J, et al. Long-term effects of insulin-like growth factor (IGF)-I treatment on serum IGFs and IGF binding proteins in adolescent patients with growth hormone receptor deficiency. Clin Endocrinol. 1995;42:399–407.

    Article  CAS  Google Scholar 

  62. Guevara-Aguirre J, Vasconez O, Martinez V, et al. A randomized, double blind, placebo controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab. 1995;80:1393–8.

    Article  PubMed  CAS  Google Scholar 

  63. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Rosenfeld RG. Two year treatment of growth hormone receptor deficiency (GHRD) with recombinant insulin-like growth factor-I in 22 children: comparison of two dosage levels and to GH treated GH deficiency. J Clin Endocrinol Metab. 1997;82:629–33.

    Article  PubMed  CAS  Google Scholar 

  64. Ranke MB, Savage MO, Chatelain PG, et al. Insulin-like growth factor I improves height in growth hormone insensitivity: two years’ results. Horm Res. 1995;44:253–64.

    Article  PubMed  CAS  Google Scholar 

  65. Rosenbloom AL, Guevara-Aguirre J, Fielder PJ, Gargosky S, Cohen P, Rosenfeld RG. Insulin-like growth factor binding proteins-2 and -3 in Ecuadorian patients with growth hormone receptor deficiency and their parents. Pediatr Adolesc Endocrinol. 1993;24:185–91.

    Google Scholar 

  66. Goddard AD, Covello R, Luoh S-M, et al. Mutations of the growth hormone receptor in children with idiopathic short stature. N Eng J Med. 1995;333:1093–8.

    Article  CAS  Google Scholar 

  67. Carlsson LM, Attie KM, Compton PG, Vitangcol RV, Merimee TJ. Reduced concentration of serum growth hormone-binding protein in children with idiopathic short stature. National Cooperative Growth Study. J Clin Endocrinol Metab. 1994;78:1325–30.

    Article  PubMed  CAS  Google Scholar 

  68. Attie KM, Carlsson LMS, Rundle AC, Sherman BM. Evidence for partial growth hormone insensitivity among patients with idiopathic short stature. J Pediatr. 1995;127:244–50.

    Article  PubMed  CAS  Google Scholar 

  69. Park P, Cohen P. Insulin-like growth factor I (IGF-I) measurements in growth hormone (GH) therapy of idiopathic short stature (ISS). Growth Horm IGF Res. 2005;15(Suppl A):S13–20.

    Article  PubMed  CAS  Google Scholar 

  70. Moore WV, Dana K, Frane J, Lippe B. Growth ­hormone responsiveness: peak stimulated growth ­hormone levels and other variables in idiopathic short stature (ISS): data from the National Cooperative Growth Study. Pediatr Endocrinol Rev. 2008;6:4–7.

    Google Scholar 

  71. Rosenbloom AL. Is there a role for recombinant insulin-like growth factor-I (rhIGF-I) in the treatment of idiopathic short stature? Lancet. 2006;368:612–6.

    Article  PubMed  CAS  Google Scholar 

  72. Midyett LK, Rogol AD, Van Meter QL, Frane J. Bright GM, on behalf of the MS301 Study Group. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first year results from a randomized clinical trial. J Clin Endocrinol Metab. 2010;95:611–19.

    Google Scholar 

  73. Rosenbloom AL, Rivkees SA. Is off label use of recombinant human insulin like growth factor (IGF)-I for growth promotion appropriate? J Clin Endocrinol Metab. 2010;95:505–8.

    Article  PubMed  CAS  Google Scholar 

  74. Guevara-Aguirre J, Rosenbloom AL, Guevara-Aguirre M, et al. Effects of heterozygosity for the E180 splice mutation causing growth hormone receptor deficiency in Ecuador on IGF-I, IGFBP-3, and stature. Growth Horm IGF Res. 2007;17:261–4.

    Article  PubMed  CAS  Google Scholar 

  75. Rosenbloom AL. IGF-I treatment of growth hormone insensitivity. In: Rosenfeld RG, Roberts CT, editors. The IGF system: molecular biology, physiology, and clinical applications. Totowa, NJ: Humana Press; 1999. p. 739–69.

    Google Scholar 

  76. Heinrichs C, Vis HL, Bergmann P, Wilton P, Bourguignon JP. Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome. Clin Endocrinol. 1993;38:647–51.

    Article  CAS  Google Scholar 

  77. Martinez V, Vasconez O, Martinez A, et al. Body changes in adolescent patients with growth hormone receptor deficiency receiving recombinant human insulin-like growth factor I and luteinizing hormone-releasing hormone analog: preliminary results. Acta Paediatr Suppl. 1994;399:133–6.

    Article  PubMed  CAS  Google Scholar 

  78. Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab. 1995;8:149–58.

    Article  PubMed  CAS  Google Scholar 

  79. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. GH Insensitivity Syndrome Collaborative Group. Long-term treatment with recombinant IGF-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab. 2007;92:902–10.

    Article  PubMed  CAS  Google Scholar 

  80. Fan Y, Menon RK, Cohen P, et al. Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J Biol Chem. 2009;24(284):19937–44.

    Article  Google Scholar 

  81. Leonard J, Samuels M, Cotterill AM, Savage MO. Effects of recombinant insulin-like growth factor I on craniofacial morphology in growth hormone insensitivity. Acta Paediatr Suppl. 1994;399:140–1.

    Article  PubMed  CAS  Google Scholar 

  82. Bjerknes R, Vesterhus P, Aarskog D. Increased neutrophil insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced functional capacity in patients with untreated Laron syndrome. Eur J Endocrinol. 1997;136:92–5.

    Article  PubMed  CAS  Google Scholar 

  83. Diamond F, Martinez V, Guevara-Aguirre J, et al. Immune function in patients with growth hormone receptor deficiency (GHRD). In: Proceedings of Endocrine Society, 78th annual meeting; 1996. vol 1, p. 276.

    Google Scholar 

  84. Le Roith D, Blakesley VA. The yin and the yang of the IGF system: immunological manifestations of GH resistance. Eur J Endocrinol. 1997;136:33–4.

    Article  PubMed  Google Scholar 

  85. Han JC, Balagopal P, Sweeten S, Darmaun D, Mauras N. Evidence for hypermetabolism in boys with constitutional delay of growth and maturation. J Clin Endocrinol Metab. 2006;91:2081–6.

    Article  PubMed  CAS  Google Scholar 

  86. Boschetti M, Larizza D, Calcaterra V, et al. Effect of environment on growth: auxological and hormonal parameters in African and Italian children. Growth Horm IGF Res. 2009;19:238–41.

    Article  PubMed  CAS  Google Scholar 

  87. Gelander L, Blum WF, Larsson L, Rosberg S, Albertsson-Wikland K. Monthly measurements of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in healthy prepubertal children: characterization and relationship with growth: the 1-year growth study. Pediatr Res. 1999;45:377–83.

    Article  PubMed  CAS  Google Scholar 

  88. Jorge AA, Souza SC, Arnhold IJ, Mendonca BB. Poor reproducibility of IGF-I and IGF binding protein-3 generation test in children with short stature and normal coding region of the GH receptor gene. J Clin Endocrinol Metab. 2002;87:469–72.

    Article  PubMed  CAS  Google Scholar 

  89. Collett-Solberg PF, Misra M. Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. The role of recombinant human insulin-like growth factor-I in treating children with short stature. J Clin Endocrinol Metab. 2008;93:10–8.

    Article  PubMed  CAS  Google Scholar 

  90. Rosenbloom AL. Recombinant human insulin like factor-1 treatment: prime time or timeout? [Commentary on “Recombinant Human Insulin Like Growth Factor-1 Treatment: Ready for Prime Time” by Bright GM, Mendoza JR, Rosenfeld RG, Endocrinol Metab Clin N Am 2009; 38:625–38] International J Pediatr Endocrinol 2009; Article ID 429684, 2009. doi:10.1155/2009/429684.

    Google Scholar 

  91. Vasconez O, Martinez V, Martinez AL, Hidalgo F, Diamond FB, Rosenbloom AL, Rosenfeld RG, Guevara-Aguirre J. Heart rate increase in patients with growth hormone receptor deficiency treated with insulin-like growth factor I. Acta Paediatr Suppl. 1994;399:137–9.

    Article  PubMed  CAS  Google Scholar 

  92. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res. 1999;51:128–34.

    Article  PubMed  CAS  Google Scholar 

  93. Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N. Long-term IGF-I treatment of children with Laron syndrome increases adiposity. Growth Horm IGF Res. 2006;16:61–4.

    Article  PubMed  CAS  Google Scholar 

  94. Klinger B, Anin S, Sibergeld A, Eshet R, Laron Z. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome. Clin Endocrinol. 1998;48:81–7.

    Article  CAS  Google Scholar 

  95. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28:20–47.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Children’s Medical Services Center, University of Florida College of Medicine, 1701 SW 16th Avenue, Gainesville, FL, 32608-1153, USA

    Arlan L. Rosenbloom M.D.

Authors
  1. Arlan L. Rosenbloom M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arlan L. Rosenbloom M.D. .

Editor information

Editors and Affiliations

  1. School of Medicine, Department of Pediatrics, The Johns Hopkins University, 600 North Wolfe St., Baltimore, 21287, Maryland, USA

    Sally Radovick

  2. , Department of Pediatrics, Children's Hospital of Buffalo, 219 Bryant St., Buffalo, 14222, New York, USA

    Margaret H. MacGillivray

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rosenbloom, A.L. (2013). Growth Hormone Insensitivity. In: Radovick, S., MacGillivray, M. (eds) Pediatric Endocrinology. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-395-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-395-4_2

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-394-7

  • Online ISBN: 978-1-60761-395-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation